Adamas Pharmaceuticals, Inc. (formerly NeuroMolecular Pharmaceuticals, Inc.) is a specialty pharmaceutical company focused on the development and commercialization of improved combination therapeutics to treat important healthcare problems. The Company's initial focus is on novel therapeutics for neurological disorders.
ArmaGen Technologies, Inc. has developed a receptor transcytosis "Trojan Horse" technology platform enabling non-invasive delivery of biotherapeutics across the blood-brain barrier. The company is initially focusing on treatment of lysosomal storage diseases, where CNS involvement cannot be addressed by current standards of care.
CellCentric, Ltd. has established a network of exclusive relationships with more than 20 of the world's leading laboratories working in epigenetics. The company continues to build and manage a portfolio of novel targets, screens and hit compounds important in the modulation of epigenetic phenomena, preparing them for full scale pharmaceutical development.
Domainex, Ltd is an integrated contract research company leveraging its proprietary Combinational Domain Hunting (CDH) technology platform to clone and express challenging genes that can then be subject to assay development and structure-based drug design. CDH identifies segments of a target gene that express high yields of protein constructs which are correctly folded, stable and soluble, providing access to high-quality recombinant protein displaying functional domains of the target.
Fate Therapeutics, Inc. is focused on exploiting the fundamental biological mechanisms that act within adult stem cells and regenerative medicine pathways to discover and develop novel small molecule and biologic modulators of cell fate. Using the most advanced rare cell isolation and cell state characterization techniques, as well as its proprietary iPSC technology to recapitulate human physiology, Fate has identified a number of novel therapeutic intervention strategies, and as such is a leader in the development of innovative regenerative medicines to treat unmet medical needs.
Heptares Therapeutics Ltd. focuses on the discovery and development of novel drugs acting at G-protein coupled receptors (GPCRs). Heptares' StaR® (Stabilized Receptor) technology enables thermo-stabilization of GPCRs, a breakthrough allowing X-ray crystallography of conformationally-constrained receptors, thereby facilitating structure-based drug design at GPCRs that have been resistant to traditional methods of drug screening.
Juventas Therapeutics, Inc. is focused on developing novel non-cell based regenerative therapies for the treatment of cardiovascular disease. The company's lead product is JVS-100, a non-viral, naked plasmid DNA encoding Stromal–cell Derived Factor 1 (SDF–1). When injected into damaged tissue, JVS-100 recruits the body’s own stem cells to the damaged region, prevents cell death and promotes new blood vessel growth. Juventas is developing JVS-100 for advanced heart failure and peripheral vascular diseases such as critical limb ischemia.
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's GFPA drug development programs include the first-generation molecule, GLYX-13, the second-generation NRX-1050 series of small molecules, and additional compounds from Naurex’s platform of novel NMDAR modulators.
NGM Biopharmaceuticals, Inc. is dedicated to the discovery and development of transformational medicines. Relying on human clinical and genetic observations, the Company has established a unique research and discovery platform to identify and validate novel targets and factors that impact the underlying etiology of metabolic diseases. Using this integrated approach NGM is generating a pipeline of new drug candidates as novel treatments for diseases such as diabetes, obesity, muscle wasting and cardiovascular disease.
Patrys Ltd. is an innovative new biotechnology company pioneering the discovery and development of human IgM antibodies for the treatment of a variety of cancers. Patrys discovers potential human antibodies through its proprietary hybridoma technology.
Redwood Bioscience, Inc. is utilizing precision protein-chemical engineering to create optimized conjugate therapeutics. Leveraging site specifically modified carrier scaffolds, Redwood is focused on developing antibody drug conjugates having superior therapeutic index profiles and peptide-based products with extended drug half-lives and enhanced potency.
Symphogen A/S is an innovative Danish biotechnology company pioneering the development of recombinant human polyclonal antibodies for the treatment and prevention of human diseases including inflammatory diseases and cancer. Symphogen's therapeutic antibodies - Symphobodies - mimic the diversity, affinity, and specificity of the human immune response and are therefore expected to offer advantages over current immunoglobulin and monoclonal antibody therapies.
Xenon Pharmaceuticals Inc. is a leading Canadian biopharmaceutical company using clinical genetic approaches to identify novel targets for a wide range of significant human diseases. By isolating the key genes underlying rare genetic disorders, the company has successfully identified drug targets for several common complex diseases. TVI's strategic investment will support efforts to find novel targets that potentially will lead to the development of innovative new treatments for atherosclerosis.
Envoy Therapeutics Inc. was acquired by Takeda, November 2012
Lectus Therapeutics' assets were acquired by UCB Pharma, November 2011.
Receptor Biologix Inc. was acquired by Symphogen A/B, December 2008
Serenex Inc. was acquired by Pfizer, April 2008
Curidium Medica Plc (CUR:LSE) acquired by Avacta Group Plc March 2009